Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

New Procedures Recommended for Improvement of Surgical Blood Transfusion

October 1, 1997
Publication
Article
OncologyONCOLOGY Vol 11 No 10
Volume 11
Issue 10

Clinical data supporting the use of leukocyte-reduced blood indicates a significant decrease in the risk of infection and cost of recovery in surgical patients, according to a panel of experts.

Clinical data supporting the use of leukocyte-reduced blood indicates a significant decrease in the risk of infection and cost of recovery in surgical patients, according to a panel of experts.

The millions of Americans who undergo surgery each year would benefit significantly from the use of leukocyte-reduced blood in transfusion, according to speakers at the recent American Society of Colon and Rectal Surgeons (ASCRS) meeting in Philadelphia. Currently reserved for transfusion in the highest-risk surgeries or cancer patients, leukocyte-reduced blood can significantly decrease the risk of infection, improve clinical outcomes, and decrease recovery time, as well as associated hospital costs with most surgical procedures.

“For surgical patients, transfusion-induced immunosuppression, which increases the risk of postoperative infection, is the single greatest mortality risk from transfusion,” said Neil Blumberg, MD, Strong Memorial Hospital, Rochester, New York. “Procedures that can minimize the risk of these infections, such as the routine use of leukocyte-reduced blood, should become a standard practice for all surgical patients requiring blood transfusions.” He added that the use of leukocyte-reduced blood for surgical patients would represent a potential annual savings of $6,000,000 to $12,000,000 for the US health-care system.

Leukocytes: Culprits of Infection

Blood transfusion has been linked with an increased occurrence of postoperative infections, such as pneumonia, wound infection, and sepsis. This increased risk has been shown in every surgical situation studied, including burn, cardiovascular, colorectal, hip, spinal, and trauma surgery.

“Since most people undergoing surgery are already sick, any measure that can eliminate the risk of additional infections, which can be life-threatening, should be adopted now,” said Richard Spence, MD, Staten Island University Hospital, New York. “Removing leukocytes from donor blood can be easily achieved through the use of blood filters either at the patient’s bedside or in the blood bank.”

Clinical Studies Indicate Reductions in Infection, Hospital Stay, and Costs

Lone Jensen, MD, Aarhus Municipal Hospital, Denmark, discussed the results of a study of 589 colorectal surgery patients that compared infection rates of leukocyte-reduced blood transfusions with allogeneic blood transfusions. She reported that when leukocyte-reduced blood was transfused, infection rates for pneumonia dropped from 23% to 3%. This rate of infection was identical to that seen in patients who received no transfusions. This study also showed that patients who received unfiltered blood had a significantly higher frequency of wound infection (12%) and rate of reoperation (16.9%) compared with patients who were transfused with leukocyte-reduced blood (0% and 3.5%).

A separate study of 915 cardiac surgery patients by van de Watering and coworkers found that leukocyte-reduced blood transfusions resulted in a noteworthy reduction in postoperative mortality by lowering the noncardiac causes of death in the study group. Noncardiac postoperative mortality was 7.6% with allogeneic blood compared with 2.5% with leukocyte-reduced blood by filtration.

“Allogeneic blood transfusion not only correlates with high infection rates but has also been significantly related to an increased length of hospital stay that is required to treat the infection,” stated Paul Tartter, MD, Mount Sinai Medical Center, New York. “Studies have shown a 15% to 35% reduction in hospital stay in surgical patients transfused with leukocyte-reduced blood. This translates into a significant reduction in the costs of hospital care.” Dr. Blumberg noted that the clinical data conclusively show that the use of leukocyte-reduced transfusions considerably decreases the risk of postoperative infections.

Articles in this issue

Vinorelbine in Non-Small-Cell Lung Cancer
Paclitaxel and Vinorelbine in Non-Small-Cell Lung Cancer
Safety Data From North American Trials of Vinorelbine
Cisplatin Alone vs Cisplatin Plus Vinorelbine in Stage IV NSCLC
Doublets and Triplets: New Drug Combinations in the Palliative Care of NSCLC
Current Management of Unresectable Non-Small-Cell Lung Cancer
Concomitant Cisplatin, Vinorelbine, and Radiation in Advanced Chest Malignancies
Vinorelbine and Carboplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer
Historical Review of Trials With Vinorelbine in Non-Small-Cell Lung Cancer
The Economics of Prostate Cancer Screening
Single-Agent Pegylated Liposomal Doxorubicin in Cancer: Current Status and Future Applications
Coalition President Urges Policy Board to Focus on the Policy and Practices Affecting Cancer Research
Researchers Studying Effects of Green Tea on Cancer Patients
New Procedures Recommended for Improvement of Surgical Blood Transfusion
Possible New Approach to Brain Tumors in AIDS Patients

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC

Russ Conroy
July 2nd 2025
Article

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.


Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.


Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.


The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Roman Fabbricatore
July 2nd 2025
Article

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

Related Content

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC

Russ Conroy
July 2nd 2025
Article

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.


Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.


Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.


The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Roman Fabbricatore
July 2nd 2025
Article

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.